BCBS Says Generic Xyrem Delay Was Antitrust Scheme

By Adam Lidgett · July 14, 2020, 8:51 PM EDT

Blue Cross Blue Shield Association has accused Jazz Pharmaceuticals in California federal court of paying off generic-drug makers to delay their rival versions of the pharmaceutical giant's brand name narcolepsy drug...

To view the full article, register now.

Documents

Case Information

Case Title

Blue Cross and Blue Shield Association v. Jazz Pharmaceuticals, Inc. et al

Case Number

3:20-cv-04667

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

July 13, 2020